Pilot Study of NanoKnife System for Ablation of Prostate Cancer

This study, initiated by AngioDynamics, Inc., will evaluate the use of the NanoKnife System as a focal therapy option for prostate cancer. It will assess the short-term safety of the device when used to ablate localized prostate cancer in low and intermediate risk subjects.

Important Risk Information

AngioDynamics, the AngioDynamics logo, NanoKnife and the NanoKnife logo are trademarks and/or registered trademarks of AngioDynamics, Inc., an affiliate or subsidiary. © 2020 AngioDynamics, Inc. GL/ON/WP/587 REV 01 12/2020